Trial Profile
Treatment outcomes in hepatitis C genotype 3 patients with/without metabolic syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2015 New trial record